Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.
A 79 year-old man was treated with Interferon alpha for chronic myelogenous leukemia and developed severe parkinsonism that resolved after Interferon alpha was stopped. Carbidopa-levodopa was associated with early improvement, but discontinuation did not result in worsening of the parkinsonism.
Sarasombath
Pichaya
P
UH School of Medicine, 1356 Lusitana St., 7th Fl., Honolulu, HI 96813, USA. spichaya@hotmail.com
Sumida
Kenneth
K
Kaku
David A
DA
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D002230:Carbidopa / Q000008:administration & dosage; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000978:Antiparkinson Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007980:Levodopa; D002230:Carbidopa